Safety Study of Oral BTA9881 to Treat RSV Infection
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I
clinical trial to determine the safety and tolerability of BTA9881 administered orally to
healthy subjects